Human Immunodeficiency Virus Type 1 Hiv 1 Infection Epidemiology Forecast Insight

DelveInsight’s ‘Human Immunodeficiency Virus Type-1 (HIV-1)Epidemiology Forecast–2030’ report delivers an in-depth understanding of the HIV-1, historical and forecasted epidemiology as well as the HIV-1 trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Overview

HIV-1 Disease Understanding

HIV is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases. HIV is a retrovirus built of RNA rather than the typical DNA. It attacks the cells (T lymphocytes and other white blood cells with CD4 receptors on their surfaces) that are a part of the body’s immune system.

 

It is spread by contact with certain bodily fluids of a person with HIV, most commonly during unprotected sex (sex without a condom or HIV medicine to prevent or treat HIV) or through sharing injection drug equipment. If left untreated, HIV can lead to the disease AIDS (acquired immunodeficiency syndrome).

 

HIV is classified into two broad categories HIV-1 and HIV-2. HIV-1 is the most common; more than 90% of people living with HIV have HIV-1. HIV-1 is further subcategorized into groups: M, N, O, and P. Among these groups, group M is most common, further divided into nine subtypes (from A to K except E and I). HIV-1 is more easily transmitted from one person to another or from mother to child. HIV-1 is spread across all over the world.

 

HIV-1 Diagnosis

HIV-1 can be diagnosed via several methods, including antibody tests, antigen/antibody tests, and Nucleic Acid Tests (NATs). Additional tests during treatment include viral load, CD4 count, and drug resistance testing. The diagnosis of HIV infection is most commonly accomplished using tests to detect antibodies to HIV in blood or oral fluid using a screening test, followed by a supplemental test for confirmation. Enzyme immunoassays (EIAs) are the most commonly used methods to perform antibody tests.

Continued in the report…..           

HIV-1 Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of HIV, total diagnosed prevalent cases of HIV, type-specific diagnosed prevalent cases of HIV, gender-specific diagnosed prevalent cases of HIV-1, diagnosed prevalent cases of HIV-1 by route of transmission, and age-specific diagnosed prevalent cases of HIV-1 scenario of HIV-1 in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

HIV-1 Detailed Epidemiology Segmentation

  • Total prevalent cases of HIV in the 7MM was found to be 1,926,925 in 2020. These cases are expected to increase by 2030 at a CAGR of 1.26% during study period (2018–2030).
  • The diagnosed prevalent cases of HIV in the 7MM was found to be 1,597,714 in 2020 which is expected to increase at a CAGR of 1.75% for the study period of 2018-2030.
  • Among 7MM, the United States has the highest diagnosed prevalent cases of HIV with 991,073 cases in 2020.
  • The diagnosed prevalent cases HIV were further divided into two broad categories, HIV-1 and HIV-2. There were total 990,974 cases of HIV-1 and 99 cases of HIV-2 in 2020 in the United States.
  • Assessments as per DelveInsight’s analysts show that the majority of cases of HIV-1 are occupied by males as compared to females. There was a total of 723,411 male and 267,563 female cases of HIV-1 in 2020 in the United States.
  • There are a plethora of modes of transmission of HIV1, among which the most common types of routes are male-to-male sexual contact which accounts for approximately 396,390 cases, Heterosexual contact (297,292), Injecting drug users (IDUs) (237,834), and other routes with 59,458 cases in 2020 in the US.
  • The age‐specific data revealed that the highest number of HIV-1 people affected with was found in the age group of 30-39 years followed by patients of age group 40-49 years (second-highest). In comparison, they are relatively less common in 13-19 years and <13 years.
  • In EU-5, France reported the highest diagnosed prevalent cases of HIV-1 with 153,253 cases in 2020, followed by Spain (127,233), Italy (116,573), UK (100,633), and Germany (82,081) in 2020.
  • In 2020, Japan had 26,870 diagnosed prevalent cases of HIV-1. These cases are expected to increase by 2030 at a CAGR of 2.61%.

Scope of the Report

  • The report covers the descriptive overview of HIV-1, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden of HIV-1.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM total prevalent cases of HIV, total diagnosed prevalent cases of HIV, type-specific diagnosed prevalent cases of HIV, gender-specific diagnosed prevalent cases of HIV-1, diagnosed prevalent cases of HIV-1 by route of transmission, and age-specific diagnosed prevalent cases of HIV-1.

Report Highlights

  • 10-Year Forecast of HIV-1
  • 7MM Coverage
  • Total Prevalent Cases of HIV,
  • Total Diagnosed Prevalent Cases of HIV,
  • Type-specific Diagnosed Prevalent Cases of HIV,
  • Gender-specific Diagnosed Prevalent Cases of HIV-1,
  • Diagnosed Prevalent Cases of HIV-1 by route of transmission,
  • Age-specific Diagnosed Prevalent Cases of HIV-1

Key Questions Answered

  • What are the disease risk and burden of HIV-1?
  • What is the historical HIV-1 patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of HIV-1 at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to HIV-1?
  • Out of the above-mentioned countries, which country would have the highest incident population of HIV-1 during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The HIV-1 report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM HIV-1 epidemiology forecast.
  • The HIV-1 epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The HIV-1 epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Human immunodeficiency virus 1 Epidemiology: Future Perspective

4. Executive Summary of HIV-1

5. Key Events

6. Disease Background and Overview

6.1. Introduction

6.2. Types of Human Immunodeficiency Virus (HIV)

6.2.1. HIV-1

6.2.1.1. Structure of HIV-1

6.2.1.2. Genetic Diversity in HIV-1

6.2.2. HIV-2

6.3. Lifecycle of HIV

6.4. Stages and Symptoms of HIV infection

6.5. Causes/Transmission of HIV infection

6.6. Pathogenesis of HIV-1

6.6.1. HIV Transmission and Early Infection

6.6.2. The Founder Virus

6.6.3. Early Events in Replication

6.6.4. HIV-1 Target Cells

6.6.4.1. T-cell Subsets

6.6.4.2. Monocytes, Macrophages, and NK Cells

6.6.5. Dissemination and Persistence in Target Tissues

6.6.5.1. Lymph Nodes and blood

6.6.5.2. Gut-associated Lymphoid Tissue (GALT)

6.6.5.3. CNS

6.6.5.4. Genital Tract

6.6.5.5. Other Cell and Tissue Types

6.6.6. Mechanism of Cell Killing

6.7. HIV-1 Diagnosis

6.7.1. Types of HIV-1 Diagnosis Tests

6.7.1.1. HIV Antibody Tests

6.7.1.2. Antigen/Antibody Test

6.7.1.3. Nucleic Acid Tests (NAT)

6.7.2. Generations of HIV tests

6.7.3. HIV-1 Diagnosis Algorithm

6.7.4. Diagnostic Guidelines and Recommendations

6.7.4.1. Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health Care Settings

6.7.4.2. British HIV Association/British Association for Sexual Health and HIV/British Infection Association Adult HIV Testing Guidelines 2020

6.8. Treatment and Management

6.8.1. Anti RetroViral Therapy drug classes

6.8.2. HIV drug resistance

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Methodology of Epidemiology

7.3. Assumptions and Rationale: 7MM

7.3.1. United States

7.3.2. Germany

7.3.3. France

7.3.4. Italy

7.3.5. Spain

7.3.6. United Kingdom

7.3.7. Japan

7.4. Prevalence of HIV in the 7MM

7.5. Diagnosed Prevalence of HIV in the 7MM

7.6. The United States

7.6.1. Prevalence of HIV in the United States

7.6.2. Diagnosed Prevalence of HIV in the United States

7.6.3. Type-specific Diagnosed Prevalence of HIV in the United States

7.6.4. Gender-specific Diagnosed Prevalence of HIV-1 in the United States

7.6.5. Diagnosed Prevalence of HIV-1 by route of transmission in the United States

7.6.6. Age-specific Diagnosed Prevalence of HIV-1 in the United States

7.7. EU-5

7.7.1. Prevalence of HIV in EU-5

7.7.2. Diagnosed Prevalence of HIV in EU-5

7.7.3. Type-specific Diagnosed Prevalence of HIV in EU-5

7.7.4. Gender-specific Diagnosed Prevalence of HIV-1 in EU-5

7.7.5. Diagnosed Prevalence of HIV-1 by route of transmission in EU-5

7.7.6. Age-specific Diagnosed Prevalence of HIV-1 in EU-5

7.8. Japan

7.8.1. Prevalence of HIV in Japan

7.8.2. Diagnosed Prevalence of HIV in Japan

7.8.3. Type-specific Diagnosed Prevalence of HIV in Japan

7.8.4. Gender-specific Diagnosed Prevalent Cases of HIV1 in Japan

7.8.5. Diagnosed Prevalent Cases of HIV-1 by route of transmission in Japan

7.8.6. Age-specific Diagnosed Prevalence of HIV1 in Japan

8. Patient Journey

9. Appendix

9.1. Bibliography

9.1.1. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Table

Table 1: Summary of HIV-1 Epidemiology (2018–2030)

Table 2: Key Events

Table 3: Difference Between HIV-1 and HIV-2

Table 5: WHO followed the following principles in developing the simplified tables

Table 6: Prevalence of HIV among 7MM during 2010 and 2020

Table 7: Incidence of HIV among 7MM during 2010 and 2020

Table 8: Coverage of people receiving ART (all ages) among 7MM during 2010 and 2020

Table 9: Prevalence of HIV in the 7MM (2018–2030)

Table 10: Diagnosed Prevalence of HIV in the 7MM (2018–2030)

Table 11: Prevalence of HIV in the United States (2018–2030)

Table 12: Diagnosed Prevalence of HIV in the United States (2018–2030)

Table 13: Type-specific Diagnosed Prevalence of HIV in the United States (2018–2030)

Table 14: Gender-specific Diagnosed Prevalence of HIV-1 in the US (2018–2030)

Table 15: Diagnosed Prevalence of HIV-1 by route of transmission in the US (2018–2030)

Table 16: Age-specific Diagnosed Prevalence of HIV-1 in the US (2018–2030)

Table 17: Prevalence of HIV in EU-5 (2018–2030)

Table 18: Diagnosed Prevalence of HIV in EU-5 (2018–2030)

Table 19: Type-specific Diagnosed Prevalence of HIV in EU-5 (2018–2030)

Table 20: Gender-specific Diagnosed Prevalent Cases of HIV1 in EU-5 (2018–2030)

Table 21: Diagnosed Prevalence of HIV-1 by route of transmission in EU-5 (2018–2030)

Table 22: Age-specific Diagnosed Prevalence of HIV-1 in EU5 (2018–2030)

Table 23: Prevalence of HIV in Japan (2018–2030)

Table 24: Diagnosed Prevalence of HIV in Japan (2018–2030)

Table 25: Type-specific Diagnosed Prevalence of HIV in Japan (2018–2030)

Table 26: Gender-specific Diagnosed Prevalent Cases of HIV1 in Japan (2018–2030)

Table 27: Diagnosed Prevalent Cases of HIV-1 by route of transmission in Japan (2018–2030)

Table 28: Age-specific Diagnosed Prevalence of HIV1 in Japan (2018–2030)

List of Figures

Figure 1: Structure of Human Immunodeficiency Virus (HIV)

Figure 2: HIV-1 Types and Subtypes

Figure 3: Structure of 9.8 kb HIV-1 Genome

Figure 4: Schematic of the HIV-1 Virion

Figure 5: Life Cycle of HIV

Figure 6: Stages of HIV Infection

Figure 7: Modes of HIV-1 Transmission

Figure 8: HIV Susceptible Cells

Figure 9: Time Course of a Typical HIV-1 Infection With the Appearance of Host Range Variants Late

Figure 10: Types of HIV-1 Diagnostic tests

Figure 11: HIV-1 Diagnostic algorithm

Figure 12: Antiretroviral Classes

Figure 13: Simplified algorithm for treatment eligibility (SLATE) algorithm

Figure 14: Algorithm for management of HIV during pregnancy

Figure 15: Prevalence of HIV in the 7MM (2018–2030)

Figure 16: Diagnosed Prevalence of HIV in the 7MM (2018–2030)

Figure 17: Prevalence of HIV in the United States (2018–2030)

Figure 18: Diagnosed Prevalence of HIV in the United States (2018–2030)

Figure 19: Type-specific Diagnosed Prevalence of HIV in the United States (2018–2030)

Figure 20: Gender-specific Diagnosed Prevalence of HIV-1 in the US (2018–2030)

Figure 21: Diagnosed Prevalence of HIV-1 by route of transmission in the US (2018–2030)

Figure 22: Age-specific Diagnosed Prevalence of HIV-1 in the US (2018–2030)

Figure 23: Prevalence of HIV in EU-5 (2018–2030)

Figure 24: Diagnosed Prevalence of HIV in EU-5 (2018–2030)

Figure 25: Type-specific Diagnosed Prevalence of HIV in EU-5 (2018–2030)

Figure 26: Gender-specific Diagnosed Prevalence of HIV-1 in EU-5 (2018–2030)

Figure 27: Diagnosed Prevalence of HIV-1 by route of transmission in EU-5 (2018–2030)

Figure 28: Age-specific Diagnosed Prevalence of HIV-1 in EU-5

Figure 29: Prevalence of HIV in Japan (2018–2030)

Figure 30: Diagnosed Prevalence of HIV in Japan (2018–2030)

Figure 31: Type-specific Diagnosed Prevalence of HIV in Japan (2018–2030)

Figure 32: Gender-specific Diagnosed Prevalent Cases of HIV1 in Japan (2018–2030)

Figure 33: Diagnosed Prevalent Cases of HIV-1 by route of transmission in Japan (2018–2030)

Figure 34: Age-specific Diagnosed Prevalence of HIV1 in Japan (2018–2030)

Forward to Friend

Need A Quote